Corrigendum to: Combined Therapy with Probiotic VSL#3 and Omega-3 Fatty Acids Attenuates Colonic Injury and Inflammation in Chronic DNBS-induced Colitis in Mice

Havvanur Yoldas ILKTAC®, Gul KIZILTAN®, Asli Devrim LANPIR®, Mehmet OZANSOY®, Mehmet Y. GUNAL®, Sine Ozmen TOGAY®, Ilknur KESKIN®, Ekrem M. OZDEMIR®, and Ulkan KILIC®

Corrigendum

https://doi.org/10.3409/fb_70-1.05

https://doi.org/10.3409/fb_69-3.15

We published the abovementioned article about probiotic mixture VSL#3 on October 6, 2021. Since the product was named VSL#3 in our purchasing process in early 2016, it is referred to as VSL#3 in our article. In addition, the product currently known as VSL#3 is not the same as De Simone Formulation. De Simone Formulation is now available as Visbiome® in the United States and Vivomixx® in Europe. The authors would like to apologise for any inconvenience caused.

Key words: Cytokines, probiotics, omega-3 fatty acids, inflammatory bowel diseases, colitis

Havvanur Yoldas ILKTAC®, Asli Devrim LANPIR®, Mehmet OZANSOY®, Mehmet Y. GUNAL®, Sine Ozmen TOGAY®, Ilknur KESKIN®, Ekrem M. OZDEMIR®, and Ulkan KILIC®

© Institute of Systematics and Evolution of Animals, PAS, Kraków, 2022
Open Access article distributed under the terms of the Creative Commons Attribution License (CC-BY)
http://creativecommons.org/licenses/by/4.0